Scientists unveil new drug‑resistant cancer approach

Cancer drug resistance is usually a repair story. Tumors survive treatment, take DNA damage, and then find a way to patch themselves back together. That is why this new result matters. A team at South Korea’s Institute for Basic Science, working with Chungnam University, says it found a way to make resistant cancer cells vulnerable again by forcing the breakdown of the proteins they use for high-precision DNA repair. (scitechdaily.com) ### What kind of repair are they going after? The target is homologous recombination — one of the cell’s cleanest ways to fix dangerous DNA breaks. Cancer drugs such as PARP inhibitors work best when tumors cannot use that pathway well. But many tumors evolve around the problem. They restore repair capacity, keep growing, and stop responding to the drug that used to work. (scitechdai([scitechdaily.com)t changed here? Instead of trying to edit mutations or block one repair enzyme at a time, the researchers went after the stability of the repair machinery itself. In a cell-based screen built around replication-stress responses, they identified a small molecule called UNI418. When they added UNI418 to cancer cells, levels of key repair proteins — especially RAD51 and CHK1 — dropped sharply. Once those proteins fell, the cells lost much of their ability to repair DNA damage. (scitechdaily.com) ### Why is that a different trick? Because the idea is not “stop repair from working today.” It is “make the repair parts disappear.” That is a deeper hit. If a resistant tumor has rebuilt homologous recombination, stripping away RAD51 and CHK1 is a bit like removing the mechanics from a pit crew instead of just slowing their tools. The repair system does not merely stall — it starts to come apart. (scitechdaily.com) ### How does UNI418 actually do that? Turns out the molecule works through an unexpected metabolic link. The team says UNI418 inhibits the lipid kinases PIKfyve and PIP5K1C, which lowers intracellular IP6. IP6 normally keeps a protein-degradation system in check. When IP6 drops, that brake comes off, the Cul4A ubiquitin ligase complex switches on, and — with help from WDR5 — tags homologous recombination proteins for destruction. (scitechdaily.com) ### Why is IP6 the interesting part? Because it connects metabolism to genome maintenance in a way that is not obvious. Cancer biology often gets described as genes on one side and metabolism on the other. This work says those categories are more entangled than they look. A signaling change in inositol phosphate metabolism can decide whether DNA-repair proteins stay stable enough for a tumor to survive therapy. (scitechdaily.com) ### Does this mean resistant cancers are now treatable? Not in patients yet. This is still preclinical work. The paper and the institutional write-up frame it as a strategy for overcoming PARP-inhibitor resistance by recreating a repair-deficient state in cells that had regained repair ability. That is promising, but it is still a lab-stage result, not a proven therapy. (ibs.re.kr)next hurdles? Safety is the big one. Healthy cells also use DNA repair, so the challenge is hitting tumors hard enough without causing unacceptable collateral damage. Delivery matters too, and so does figuring out which cancers depend most on this pathway and would actually benefit from combination treatment with existing PARP inhibitors. (discovermagazine.com)sically, the team found a way to re-open a weakness that resistant tumors had closed. If the approach holds up, it could turn “this drug stopped working” into “this tumor can be made sensitive again” — which is one of the most valuable moves in cancer treatment. (scitechdaily.com)